TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›REVB›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

REVELATION BIOSCIENCES, INC. (REVB) financials

Income statement

REVELATION BIOSCIENCES, INC. (REVB) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income——-$12.0M-$10.9M-$8.66M-$7.98M-$9.07M
Net income-$3.64K-$1.63M-$12.0M-$10.8M-$120K-$15.0M-$8.91M
EPS (diluted)—-$0.03-$42.50-$149.20-$8.44-$1,052.16-$23.95

Cash flow

REVELATION BIOSCIENCES, INC. (REVB) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow—-$217K-$11.1M-$11.2M-$7.29M-$18.3M-$8.27M
Capital expenditures——$132K——$19.2K—
Free cash flow——-$11.2M——-$18.3M—
Share buybacks——$35.5M$35.5M———

Balance sheet

REVELATION BIOSCIENCES, INC. (REVB) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents—$11.7K$1.27M$5.25M$12.0M$6.50M$10.7M
Total assets$22.7K$74.2M$2.04M$5.50M$12.2M$6.62M$11.6M
Total liabilities$26.3K$6.34M$2.14M$4.45M$5.56M$1.91M$2.72M
Shareholders' equity-$3.64K$3.41M-$99.5K$1.05M$6.65M$4.71M$8.86M
Retained earnings-$3.64K-$5.69M-$14.5M-$25.3M-$25.5M-$40.5M-$49.4M
Shares (wtd avg diluted)—2.41M282K72.6B14.2B14.3B621K

Every figure is extracted from REVELATION BIOSCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does REVB pay a dividend?
REVELATION BIOSCIENCES, INC. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full REVB analysis — verdict, score & filings →Is REVB a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.